Presentations & Publications

We are proud of our scientific progress, much of which has been documented via various presentations and publications.

Since 2011, our proprietary platform has enabled the design of three new clinical drug candidates, resulting in four clinical programs. Our scientific progress has been documented in various national and international presentations and publications.

June 2015

A Phase 1 Clinical Trial of PRN1008, An Oral, Reversible, Covalent BTK Inhibitor Demonstrates Clinical Safety and Therapeutic Levels of BTK Occupancy Without Sustained Systemic Exposure

June 2015

Preclinical Characterization of PRN1008, A Novel Reversible Covalent Inhibitor of BTK That Shows Efficacy In A Rat Model of Collagen-Induced Arthritis

May 2015

Prolonged and tunable residence time using reversible covalent kinase inhibitors.

May 2015

Efficacy in collagen induced arthritis models with a selective, reversible covalent Bruton’s Tyrosine Kinase (BTK) inhibitor PRN473 is driven by durable target occupancy rather than extended plasma exposure

January 2015

Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694

November 2014

Irreversible covalent pan-FGFR Inhibitors are highly efficacious against FGFR-dependent cancers.

November 2014

Development of a Disease Model of Bruton’s Tyrosine Kinase (BTK) Inhibition by PRN473 in Rat Collagen-Induced Arthritis (rCIA)

May 2012

Discovery of a highly potent, selective reversible covalent inhibitor of JAK3 kinase [abstract]

Advancing Promising Therapies

Principia is now a Sanofi company.

As of September 28, 2020, Sanofi and Principia have joined forces to expand and accelerate the potential benefits of therapies for patients with immune-mediated diseases. We will work together to bring these novel therapies to patients faster. Read press release.

Enter Website